Compare GROY & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GROY | RGNX |
|---|---|---|
| Founded | 2020 | 2008 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 618.0M | 661.2M |
| IPO Year | 2021 | 2015 |
| Metric | GROY | RGNX |
|---|---|---|
| Price | $4.05 | $13.85 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $5.00 | ★ $30.29 |
| AVG Volume (30 Days) | ★ 3.7M | 612.2K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $14,464,000.00 | ★ $161,318,000.00 |
| Revenue This Year | $71.94 | $132.80 |
| Revenue Next Year | $66.48 | $48.47 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 86.30 | ★ 91.30 |
| 52 Week Low | $1.16 | $5.04 |
| 52 Week High | $4.49 | $13.99 |
| Indicator | GROY | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 63.20 |
| Support Level | $3.96 | $12.61 |
| Resistance Level | $4.49 | $13.42 |
| Average True Range (ATR) | 0.25 | 0.82 |
| MACD | -0.01 | 0.07 |
| Stochastic Oscillator | 53.54 | 93.12 |
Gold Royalty Corp is a precious metals-focused royalty and mineral streaming company. The company offers creative financing solutions to the metals and mining industry. The company's mission is to acquire royalties, streams and similar interests at varying stages of the mine life cycle to build a balanced portfolio offering near, medium and longer-term attractive returns for investors. It has its business as a single operating segment, being the investment in royalty and mineral stream interests. The company derives maximum revenue from Canada.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.